A 2025 systematic review and meta analysis, which essentially compiles and examines existing studies as a whole to draw broad conclusions, does not regard tirzepatide as superior to semaglutide for chronic weight management
These include symptoms of pancreatitis, such as severe upper abdominal pain that may radiate to the back, accompanied by nausea and vomiting
By mimicking both GLP-1 and GIP, tirzepatide provides a dual-action effect that helps manage hunger, slow digestion, and stabilize blood sugar more efficiently
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for the treatment of type 2 diabetes and obesity
Response varies by starting weight, dose, diet, activity level, and other individual factors, and we will not promise a specific timeline